medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-682Research ArticleСтатьиТрадиционные подходы и новые возможности в лечении ANCA-ассоциированного васкулита. Клинические примерыTraditional approaches and new opportunities in treatment of ANCA-associated vasculitis. Clinical examplesВетшеваМ. С.VetshevaM. S.noemail@neicon.ruЛоссК. Э.LossK. E.noemail@neicon.ruПодкорытоваО. Л.PodkorytovaO. L.noemail@neicon.ruДьяковаЕ. Н.DyakovaE. N.noemail@neicon.ruФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава РоссииРоссияFirst Moscow State Medical University n.a. I. M. SechenovRussian FederationГБУЗ г. Москвы «Городская клиническая больница № 13» Департамента здравоохранения г. МосквыРоссияCity Clinical Hospital No. 13; MoscowRussian Federation201812062018218Неотложная медицина3542Copyright © Ветшева М.С., Лосс К.Э., Подкорытова О.Л., Дьякова Е.Н., 20182018Ветшева М.С., Лосс К.Э., Подкорытова О.Л., Дьякова Е.Н.Vetsheva M.S., Loss K.E., Podkorytova O.L., Dyakova E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/682

ANCA-ассоциированные системные васкулиты - это группа аутоиммунных заболеваний, поражающих сосуды мелкого калибра с развитием некротизирующего васкулита, для которых характерна разнообразная клиническая картина с вовлечением в воспалительный процесс жизненно важных органов - легких, почек, ЛОР-органов, ЦНС, желудочно-кишечного тракта и с серьезным прогнозом. Лечение ANCA-СВ включает в себя терапию кортикостероидами, цитостатиками, моноклональными антителами. Однако при развитии жизнеугрожающих состояний (кровохарканье, легочное кровотечение, цереброваскулит) применяются аферентные методы лечения: терапевтический плазмаобмен, терапевтический плазмаферез (ТРЕ) и двойная каскадная плазма фильтрация (DFPP).

ANCA-associated vasculitis is a group of autoimmune diseases affecting small caliber vessels with the development of necrotizing vasculitis, which are characterized by a diverse clinical picture with the involvement of the inflammatory process of vital organs - lungs, kidneys, upper respiratory tract, central nervous system, gastrointestinal tract - and with a serious prognosis. The treatment of ANCA-CB includes therapy with corticosteroids, cytostatics, monoclonal antibodies. However, with the development of life-threatening conditions (hemoptysis, pulmonary bleeding, cerebrovascular) aferente treatments are used, i.e. herapeutic plasma exchange, therapeutic plasmapheresis (TPE) and double filtration plasmapheresis (DFPP).

терапевтический плазмаферездвойная каскадная плазма фильтрацияANCA-ассоциированный васкулитANCA-associated vasculitistherapeutic plasmapheresisdouble filtration plasmapheresisReferencesJennette J. Overview of the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clin Exp Nephrol. 2013 Oct; 17 (5): 603-606.Jennette J. Overview of the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clin Exp Nephrol. 2013 Oct; 17 (5): 603-606.Van Daalen E., Ferrario F., Noël L. H., Waldherr R. Hagen E. C., Bruijn J. A., Bajema I.M.: Twenty-five years of RENHIS: a history of histopathological studies within EUVAS / van Daalen E., Ferrario F., Noël L. H., Waldherr R. Hagen E. C., Bruijn J. A., Bajema I. M. // Nephrol. Dial. Transplant.- 2015. -30.- Р. 31-36.Van Daalen E., Ferrario F., Noël L. H., Waldherr R. Hagen E. C., Bruijn J. A., Bajema I.M.: Twenty-five years of RENHIS: a history of histopathological studies within EUVAS / van Daalen E., Ferrario F., Noël L. H., Waldherr R. Hagen E. C., Bruijn J. A., Bajema I. M. // Nephrol. Dial. Transplant.- 2015. -30.- Р. 31-36.Yates M, Watts RA, Bajema IM, et al. EULAR/ ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Jun 23. pii: annrheum-dis-2016-209133. doi: 10.1136/annrheum-dis-2016-209133.Yates M, Watts RA, Bajema IM, et al. EULAR/ ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Jun 23. pii: annrheum-dis-2016-209133. doi: 10.1136/annrheum-dis-2016-209133.Watts RA, Lane SE, Bentham G, Scott DGI Epidemiology of systemic vasculitis - a 10 year study.- Arthritis Rheum 2000; 43: 422-427.Watts RA, Lane SE, Bentham G, Scott DGI Epidemiology of systemic vasculitis - a 10 year study.- Arthritis Rheum 2000; 43: 422-427.Fujimoto S, Watts R, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibodyassociated vasculitis between Japan and the UK. - Rheumatology 2011; 50: 1916-1920.Fujimoto S, Watts R, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibodyassociated vasculitis between Japan and the UK. - Rheumatology 2011; 50: 1916-1920.Бекетова Т.В. АНЦА-ассоциированный системный васкулит. Нефрология. Национальное руководство / гл. ред. Н. А. Мухин.- М.: ГЭОТАР-Медиа, 2014.Бекетова Т.В. АНЦА-ассоциированный системный васкулит. Нефрология. Национальное руководство / гл. ред. Н. А. Мухин.- М.: ГЭОТАР-Медиа, 2014.Manno L. et al. Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study.- BMC Nephrology 2015. 16:88. DOI: 10.1186/ sl2882-015-0082-9.Manno L. et al. Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study.- BMC Nephrology 2015. 16:88. DOI: 10.1186/ sl2882-015-0082-9.Hilhorst М. et al. Connective tissue growth factor and the cicatrization of cellular crescents in ANCA-associated glomerulonephritis.- NDT. Volume 30, Issue 8. Pp. 1291-1299.Hilhorst М. et al. Connective tissue growth factor and the cicatrization of cellular crescents in ANCA-associated glomerulonephritis.- NDT. Volume 30, Issue 8. Pp. 1291-1299.Jeffrey L. Winters. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines.- American Society of Hematology. Hematology 2012. 7-12.Jeffrey L. Winters. Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines.- American Society of Hematology. Hematology 2012. 7-12.Falk R. J., Terrell R. S., Charles L. A. & Jennette J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.- Proc. Natl Acad. Sci. USA 87, 41154119 (1990).Falk R. J., Terrell R. S., Charles L. A. & Jennette J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.- Proc. Natl Acad. Sci. USA 87, 41154119 (1990).Ewert B. H., Becker M.E., Jennette J. C. & Falk R. J. Antimyeloperoxidase antibodies induce neutrophil adherence to cultured human endothelial cells.- Ren. Fail. 17, 125-133 (1995).Ewert B. H., Becker M.E., Jennette J. C. & Falk R. J. Antimyeloperoxidase antibodies induce neutrophil adherence to cultured human endothelial cells.- Ren. Fail. 17, 125-133 (1995).Van der Woude F., Rasmussen N., Lobatto S. et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis.- Lancet 1985; 1: 425-9.Van der Woude F., Rasmussen N., Lobatto S. et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis.- Lancet 1985; 1: 425-9.Falk R. J., Terrell R. S., Charles L. A. & Jennette J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.- Proc. Natl Acad. Sci. USA 87, 41154119 (1990).Falk R. J., Terrell R. S., Charles L. A. & Jennette J. C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.- Proc. Natl Acad. Sci. USA 87, 41154119 (1990).Roth A.J. et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis.- J. Am. Soc. Nephrol. 23, 545-555 (2012).Roth A.J. et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis.- J. Am. Soc. Nephrol. 23, 545-555 (2012).Berden et al. Histopathologic classification of ANCA-associated glomerulonephritis.- J Am Soc Nephrol. 2010 Oct; 21 (10): 1628-36. doi: 10.1681/ASN.2010050477. Epub 2010 Jul 8.Berden et al. Histopathologic classification of ANCA-associated glomerulonephritis.- J Am Soc Nephrol. 2010 Oct; 21 (10): 1628-36. doi: 10.1681/ASN.2010050477. Epub 2010 Jul 8.Kallenberg CG et al. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention.-Am J Kidney Dis. 2013 Dec; 62 (6): 1176-87. doi: 10.1053/j.ajkd.2013.05.009. Epub 2013 Jun 28.Kallenberg CG et al. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention.-Am J Kidney Dis. 2013 Dec; 62 (6): 1176-87. doi: 10.1053/j.ajkd.2013.05.009. Epub 2013 Jun 28.Luqmani R. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis / Luqmani R, Bacon P, Moots R, Janssen B, et al. // QJM. -1994.- 87.- Р. 671-678.Luqmani R. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis / Luqmani R, Bacon P, Moots R, Janssen B, et al. // QJM. -1994.- 87.- Р. 671-678.Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis / Taylorn SR, Salama AD, Joshi L, Pusey CD, Lightman SL. // Arthritis Rheum. - 2009.- 60.- 5.- Р. 1540-1547.Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis / Taylorn SR, Salama AD, Joshi L, Pusey CD, Lightman SL. // Arthritis Rheum. - 2009.- 60.- 5.- Р. 1540-1547.Walsh M, Casian A, Flossmann O et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013; 84: 397-402.Walsh M, Casian A, Flossmann O et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 2013; 84: 397-402.Ward DM, Conventional apheresis therapies: a review.- J Clin Apher. 2011; 26 (5): 230-8. doi: 10.1002/jca.20302. Epub 2011 Aug 31.Ward DM, Conventional apheresis therapies: a review.- J Clin Apher. 2011; 26 (5): 230-8. doi: 10.1002/jca.20302. Epub 2011 Aug 31.Jayne DRW, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.- J Am Soc Nephrol 2007; 18: 2180-2188.Jayne DRW, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.- J Am Soc Nephrol 2007; 18: 2180-2188.

The authors declare that there are no conflicts of interest present.